New Zealand: These 33 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: capsaicin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 14, 2023
Generic Entry Controlled by: New Zealand Patent 541,956
Patent Title: Therapeutic patch with polysiloxane matrix comprising capsaicin

QUTENZA is a drug marketed by Averitas. There are seven patents protecting this drug.

This drug has eighty-five patent family members in twenty-nine countries. There has been litigation on patents covering QUTENZA

See drug price trends for QUTENZA.

The generic ingredient in QUTENZA is capsaicin. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the capsaicin profile page.

Generic name: letermovir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 02, 2023
Generic Entry Controlled by: New Zealand Patent 543,317
Patent Title: Substituted dihydrochinazolines having antiviral properties

PREVYMIS is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug.

This drug has eighty-five patent family members in forty-five countries.

See drug price trends for PREVYMIS.

The generic ingredient in PREVYMIS is letermovir. One supplier is listed for this generic product. Additional details are available on the letermovir profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2023
Generic Entry Controlled by: New Zealand Patent 543,905
Patent Title: Peptides that bind to the erythropoietin receptor

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: siponimod fumaric acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2023
Generic Entry Controlled by: New Zealand Patent 543,241
Patent Title: Immunosuppressant compounds and compositions

MAYZENT is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has one hundred and forty patent family members in thirty-nine countries.

See drug price trends for MAYZENT.

The generic ingredient in MAYZENT is siponimod fumaric acid. One supplier is listed for this generic product. Additional details are available on the siponimod fumaric acid profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: New Zealand Patent 544,026
Patent Title: Phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

JANUMET is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET

See drug price trends for JANUMET.

The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: New Zealand Patent 544,026
Patent Title: Phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

JANUMET XR is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR

See drug price trends for JANUMET XR.

The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.

Generic name: sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: New Zealand Patent 544,026
Patent Title: Phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

JANUVIA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug and one Paragraph IV challenge. Twelve tentatively approved generics are ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA

See drug price trends for JANUVIA.

The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.

Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: New Zealand Patent 544,026
Patent Title: Phosphoric acid salt of 4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine

JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC

The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: New Zealand Patent 544,747
Patent Title: Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.

This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: New Zealand Patent 544,747
Patent Title: Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists

ORILISSA is a drug marketed by Abbvie Inc. There are six patents protecting this drug.

This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: cariprazine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: New Zealand Patent 544,999
Patent Title: (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists

VRAYLAR is a drug marketed by Allergan. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: New Zealand Patent 545,984
Patent Title: 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: dabigatran etexilate mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: New Zealand Patent 578,586
Patent Title: 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament

PRADAXA is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug and two Paragraph IV challenges. Ten tentatively approved generics are ready to enter the market.

This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA

See drug price trends for PRADAXA.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.

Generic name: cabazitaxel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: New Zealand Patent 545,835
Patent Title: Dimethoxy docetaxel acetone solvate and method for the preparation thereof

JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT

The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.

Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: New Zealand Patent 546,337
Patent Title: Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80

DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT

See drug price trends for DUETACT.

The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: New Zealand Patent 547,466
Patent Title: Method for the production of a solid, orally applicable pharmaceutical composition comprising 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5yl}-methyl)-2-thiophenecarboxamide

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Two tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.

Generic name: latanoprostene bunod
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: New Zealand Patent 548,271
Patent Title: Prostaglandin nitrooxyderivatives

VYZULTA is a drug marketed by Bausch And Lomb. There are four patents protecting this drug.

This drug has fifty-three patent family members in thirty-eight countries.

See drug price trends for VYZULTA.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.

Generic name: ivacaftor; lumacaftor
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: New Zealand Patent 567,892
Patent Title: Heterocyclic modulators of ATP-binding cassette transporters containing cycloalkyl or heterocycloalkyl groups

ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.

This drug has four hundred and fifty patent family members in thirty-five countries.

See drug price trends for ORKAMBI.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.

Generic name: lomitapide mesylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: New Zealand Patent 549,721
Patent Title: Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects

JUXTAPID is a drug marketed by Amryt. There are eight patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries. There has been litigation on patents covering JUXTAPID

See drug price trends for JUXTAPID.

The generic ingredient in JUXTAPID is lomitapide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lomitapide mesylate profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: New Zealand Patent 549,867
Patent Title: Prodrugs of piperazine and substituted piperidine antiviral agents

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: fostemsavir tromethamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: New Zealand Patent 585,294
Patent Title: Prodrugs of piperazine and substituted piperidine antiviral agents

RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.

This drug has thirty-nine patent family members in thirty countries.

See drug price trends for RUKOBIA.

The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: New Zealand Patent 550,464
Patent Title: Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof

SYNJARDY is a drug marketed by Boehringer Ingelheim. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY

See drug price trends for SYNJARDY.

The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: New Zealand Patent 550,464
Patent Title: Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof

SYNJARDY XR is a drug marketed by Boehringer Ingelheim. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR

See drug price trends for SYNJARDY XR.

The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.

Generic name: aliskiren hemifumarate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: New Zealand Patent 548,823
Patent Title: Galenic formulations of organic compounds (oral dosage of aliskiren)

TEKTURNA is a drug marketed by Noden Pharma. There are three patents protecting this drug and two Paragraph IV challenges.

This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA

See drug price trends for TEKTURNA.

The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.

Generic name: etonogestrel
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: New Zealand Patent 549,877
Patent Title: X-ray visible drug delivery device

IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.

This drug has thirty-two patent family members in twenty-six countries.

The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.

Generic name: teriparatide recombinant human
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: New Zealand Patent 549,099
Patent Title: Medication dispensing apparatus with spring-driven locking feature enabled by administration of final dose

FORTEO is a drug marketed by Lilly. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO

See drug price trends for FORTEO.

The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: New Zealand Patent 550,417
Patent Title: Multi-phase contraceptive preparation based on a natural estrogen

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: umeclidinium bromide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: New Zealand Patent 549,997
Patent Title: Quinuclidine derivatives such as 4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide as muscarinic acetylcholine receptor antagonists

INCRUSE ELLIPTA is a drug marketed by

This drug has one hundred and seventy-seven patent family members in thirty-nine countries.

See drug price trends for INCRUSE ELLIPTA .

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: New Zealand Patent 550,796
Patent Title: 4-phenylamino-quinazolin-6-yl-amides

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety patent family members in forty-seven countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.

Generic name: indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: New Zealand Patent 550,625
Patent Title: Inhaler device with capsule piercing means comprising a pair of opposed spring biased push buttons that each include at least one piercing element

ARCAPTA NEOHALER is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER

See drug price trends for ARCAPTA NEOHALER.

The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.

Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: New Zealand Patent 550,625
Patent Title: Inhaler device with capsule piercing means comprising a pair of opposed spring biased push buttons that each include at least one piercing element

UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON

See drug price trends for UTIBRON.

The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: New Zealand Patent 551,839
Patent Title: Stable crystal of 4-oxoquinoline compound

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.

This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: vandetanib
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: New Zealand Patent 550,931
Patent Title: Pharmaceutical compositions comprising ZD6474

CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.

This drug has one hundred and forty-two patent family members in forty-three countries.

See drug price trends for CAPRELSA.

The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.

Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: New Zealand Patent 551,591
Patent Title: Coated tablet formulation and method

KOMBIGLYZE XR is a drug marketed by Astrazeneca Ab. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR

See drug price trends for KOMBIGLYZE XR.

The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.

Generic name: saxagliptin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: New Zealand Patent 551,591
Patent Title: Coated tablet formulation and method

ONGLYZA is a drug marketed by Astrazeneca Ab. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA

See drug price trends for ONGLYZA.

The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.